BCORL1 and myelodysplastic syndrome: Poor-risk mutation carriers with AA have a 40% higher risk of clonal evolution to MDS or acute myeloid leukemia (AML) compared with patients with PIGA, BCOR, and BCORL1 mutations (27–30).